Accessibility Menu
Immuron logo

Immuron(ASX) IMC

Market CapA$17.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-99%
5 Year-66%
1 Year-21%
1 Month+69%
A$0.05
+35.00%
+0.01Today
Immuron last closing stock price
MetricPriceDate
Last closeAUD 0.052026-09-07
Immuron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+42.11%AUD 0.042026-08-31
1 month+68.75%AUD 0.032026-08-06
3 month+28.57%AUD 0.042026-06-04
Year to date+50%AUD 0.042025-12-31
1 year-20.59%AUD 0.072025-09-04
3 year-27.03%AUD 0.072023-09-07
5 year-66.25%AUD 0.162021-05-26
Since inception-99.35%AUD 6.191999-04-30

Immuron Financials at a Glance

Market Cap

A$17.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$15.00M

Net Income (TTM)

-A$9.05M

EPS (TTM)

-A$0.01

P/E Ratio

-4.19

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.05

Volume

0

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.06

52-Week Range

A$0.03 - A$0.10

Estimated Earnings Date

Feb 19, 2027

IMC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuron

Immuron Limited is an Australian biopharmaceutical company focused on the development and commercialization of polyclonal antibodies. Established in 1994 and headquartered in Carlton, the company operates in the biotechnology sector, offering innovative solutions for gastrointestinal health and immune support.

Products and Services
  • Travelan: An over-the-counter remedy for travelers' diarrhea and digestive health
  • Protectyn: An immune supplement for digestive function and liver support
  • Pipeline candidates: Including IMM-124E and IMM-529 for gastrointestinal infections
Growth Outlook
  • Travelan is in Phase III trials in the U.S. for travelers' diarrhea prevention
  • IMM-529 is advancing in Phase I/IIa trials for recurrent Clostridium difficile infections
  • Strategic alliances with military research institutes enhance product development
Financial Highlights
  • Recent quarterly revenue of AUD 4.18 million, showing growth potential
  • Cash and short-term investments totaled AUD 9.99 million, providing operational stability
  • Current ratio of 8.04 indicates strong liquidity and financial health
Immuron Limited is positioned to capitalize on the growing demand for effective gastrointestinal and immune health solutions. The company's commitment to research and development, alongside its strategic partnerships, enhances its potential for future growth. Recent financial data reflects a solid cash position, which supports ongoing clinical trials and product development. With a focus on innovative therapies, Immuron is well-placed to make significant contributions to the biopharmaceutical landscape.
AI Generated • Aug 23, 2026

Industry

Biotechnology

CEO

Steven Lydeamore, MBA

Headquarters

Carlton, VIC 3053, AU

IMC Financials

Key Financial Metrics (TTM)

Gross Margin

64.50%

Operating Margin

-61.39%

Net Income Margin

-49.77%

Return on Equity

-31.88%

Return on Capital

-43.03%

Return on Assets

-29.54%

Earnings Yield

-23.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$17.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

322.85M

Volume

0

Avg. Volume

210.43K

Financials (TTM)

Gross Profit

A$9.74M

Operating Income

-A$10.08M

EBITDA

-A$10.04M

Operating Cash Flow

-A$9.20M

Capital Expenditure

-A$4.76K

Free Cash Flow

-A$9.21M

Cash & ST Invst.

A$9.02M

Total Debt

A$0.00

Immuron Performance Analysis

Immuron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,804,705135.8%
20242024-06-30AUD 4,902,865171.7%
20252025-06-30AUD 7,287,00248.6%
20262026-06-30AUD 7,713,6015.9%
Immuron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3156.8%
Q42025-06-30-17.6%
Q22025-12-3127.1%
Q42026-06-30-15.7%
Immuron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0232.8%
20242024-06-30AUD -0.0383.1%
20252025-06-30AUD -0.02-25.7%
20262026-06-30AUD -0.01-42.9%
Immuron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3148.8%
Q42025-06-30-7.3%
Q22025-12-3140.2%
Q42026-06-3015.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$3.53M

+38.5%

Gross Profit

A$2.32M

+32.2%

Gross Margin

65.78%

N/A

Market Cap

A$17.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.49M

N/A

Employees

7

N/A

Net Income

-A$1.92M

+60.5%

EBITDA

-A$2.43M

+27.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$9.02M

-22.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$1.25M

-9.9%

Inventory

A$2.27M

+43.5%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-29.54%

N/A

Return on Invested Capital

-42.25%

N/A

Free Cash Flow

-A$589.81K

+84.8%

Operating Cash Flow

-A$589.81K

+84.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AT1.AXAtomo Diagnostics Limited
A$0.02-5.26%
BTC.AXBTC Health Limited
A$0.06+0.00%
NTI.AXNeurotech International Limited
A$0.01-3.70%
NOX.AXNoxopharm Limited
A$0.07-6.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About IMC

What is the current price of Immuron?

Immuron is trading at A$0.05 per share.

What is the 52-week range for Immuron?

Over the past 52 weeks, Immuron has traded between A$0.03 and A$0.10.

How much debt does Immuron have?

As of the most recent reporting period, Immuron reported total debt of A$0.00.

How much cash does Immuron have on hand?

Immuron reported A$9.02M in cash and cash equivalents in its most recent financial results.

What is Immuron’s dividend yield?

Immuron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.